Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06376058
Other study ID # 434/06-06-2022
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date January 10, 2024
Est. completion date January 10, 2026

Study information

Verified date April 2024
Source Aretaieion University Hospital
Contact Kassiani Theodoraki, PhD, DESA
Phone 6974634162
Email ktheodoraki@hotmail.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This will be a prospective randomized study, aiming at comparing an intrathecal fixed dose of chloroprocaine 1% versus an intrathecal fixed dose of ropivacaine 0.75% in elective cesarean sections


Description:

Neuraxial techniques are the anesthetic techniques of choice in contemporary obstetric anesthesia practice, with a definitive superiority as compared to general anesthesia, since, by their use, serious complications involving the airway can be avoided. Combined spinal-epidural anesthesia has become the favorable technique for both elective and emergency cesarean sections. Various local anesthetics have been used, but ropivacaine is the drug of choice in most hospitals in Greece. However, chloroprocaine is a preferable local anesthetic in USA due to its quick and predictable onset of action. Chloroprocaine was initially used in 1980, but it became obsolete in those years due to neurological symptoms associated with its use caused mainly by the presence of sodium bisulfite and disodium ethylenediaminetetraacetate (EDTA) in the early formulations. Nowadays, new formulations of the drug without EDTA makes chloroprocaine safe for use. The aim of the current randomized controlled trial will be to compare the effect of an intrathecal fixed dose of chloroprocaine versus an intrathecal fixed dose of ropivacaine in parturients subjected to elective cesarean section under combined spinal-epidural anesthesia.


Recruitment information / eligibility

Status Recruiting
Enrollment 60
Est. completion date January 10, 2026
Est. primary completion date January 10, 2026
Accepts healthy volunteers No
Gender Female
Age group 18 Years to 48 Years
Eligibility Inclusion Criteria: - adult parturients, American Society of Anesthesiologists (ASA) I-II, - singleton gestation>37 weeks - elective cesarean section Exclusion Criteria: - American Society of Anesthesiologists (ASA) > III - age < 18 years - singleton gestation <37 weeks - Body Mass Index (BMI) >40 kg/m2 - Body weight <50 kg - Body weight>100 kg - height<150 cm - height>180 cm - multiple gestation - emergency delivery - fetal abnormality - fetal distress - pregnancy-induced pathology such as preeclampsia, eclampsia, premature labor, placental abnormalities - pregnancy- induced diseases such as hepatic failure, pseudocholinesterase deficiency, neuromuscular diseases - lack of informed consent - contraindication for regional anesthesia such as thrombocytopenia, coagulation abnormalities, allergy to local anesthetics

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Chloroprocaine 1% Injectable Solution
• in parturients allocated to the chloroprocaine group, a fixed dose of chloroprocaine 1% will be administered intrathecally
Ropivacaine 0.75% Injectable Solution
• in parturients allocated to the ropivacaine group, a fixed dose of ropivacaine 0.75% will be administered intrathecally

Locations

Country Name City State
Greece Aretaieion University Hospital Athens

Sponsors (1)

Lead Sponsor Collaborator
Aretaieion University Hospital

Country where clinical trial is conducted

Greece, 

References & Publications (4)

Baribeault T, Suss S. Spinal Anesthesia with 2-Chloroprocaine and Dexmedetomidine for Cesarean Section: A Case Report. AANA J. 2023 Jun;91(3):194-196. — View Citation

Maes S, Laubach M, Poelaert J. Randomised controlled trial of spinal anaesthesia with bupivacaine or 2-chloroprocaine during caesarean section. Acta Anaesthesiol Scand. 2016 May;60(5):642-9. doi: 10.1111/aas.12665. Epub 2015 Nov 26. — View Citation

Saporito A, Ceppi M, Perren A, La Regina D, Cafarotti S, Borgeat A, Aguirre J, Van De Velde M, Teunkens A. Does spinal chloroprocaine pharmacokinetic profile actually translate into a clinical advantage in terms of clinical outcomes when compared to low-dose spinal bupivacaine? A systematic review and meta-analysis. J Clin Anesth. 2019 Feb;52:99-104. doi: 10.1016/j.jclinane.2018.09.003. Epub 2018 Sep 18. — View Citation

Singariya G, Choudhary K, Kamal M, Bihani P, Pahuja H, Saini P. Comparison of analgesic efficacy of intrathecal 1% 2-chloroprocaine with or without fentanyl in elective caesarean section: A prospective, double-blind, randomised study. Indian J Anaesth. 2021 Feb;65(2):102-107. doi: 10.4103/ija.IJA_816_20. Epub 2021 Feb 10. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Time from spinal anesthesia to T10 block (min) time required from spinal anesthetic injection to anesthetic block up to the 10th thoracic neurotome intraoperative
Primary Time from spinal anesthesia to T4 block (min) time required from spinal anesthetic injection to anesthetic block up to the 4th thoracic neurotome intraoperative
Primary Time of spinal anesthesia to Bromage =3 time required from spinal anesthetic injection to complete motor block (Bromage scale=3, where Bromage=0, no block; Bromage=1, partial block; Bromage=2, almost complete block; Bromage=3, complete block intraoperative
Primary level of sensory block every 3 min measurement of sensory block every 3 minutes after spinal anesthesia during the first 15 minutes intraoperative
Primary level of sensory block every 15 min measurement of sensory block every 15 minutes from spinal anesthesia to the end of the surgery intraoperative
Primary highest level of sensory block measurement of the highest level of sensory block after intrathecal infusion of local anesthetic intraoperative
Primary time from spinal anesthesia to highest level of sensory block time from the performance of spinal anesthesia to the highest level of sensory block intraoperative
Primary duration of sensory block measurement of time required for the sensory block to regress from sensory level T4 to sensory level T12/L2 intraoperative
Primary pain at surgical incision pain at skin incision using Visual Analogue Scale (VAS), where VAS=0, no pain; VAS=10, worst pain imaginable intraoperative
Primary pain at neonatal delivery pain at neonatal delivery using VAS scale, where VAS=0, no pain; VAS=10, worst pain imaginable intraoperative
Primary pain at peritoneal manipulation pain at peritoneal manipulation using VAS scale, where VAS=0, no pain; VAS=10, worst pain imaginable intraoperative
Primary pain at Post Anesthesia Care Unit (PACU) admission pain at Post Anesthesia Care Unit (PACU) admission using VAS scale, where VAS=0, no pain; VAS=10, worst pain imaginable 1 hour postoperatively
Primary pain at Post Anesthesia Care Unit (PACU) discharge pain at Post Anesthesia Care Unit (PACU) discharge using VAS scale, where VAS=0, no pain; VAS=10, worst pain imaginable 1 hour postoperatively
Primary need for rescue analgesia intraoperatively need for rescue analgesia during the operation, via epidural catheter or intravenously intraoperative
Primary Bromage scale every 3 min after spinal anesthesia measurement of bromage scale every 3 minutes after spinal anesthesia during the first 15 minutes intraoperative
Primary Bromage scale every 15 min measurement of bromage scale every 15 minutes from spinal anesthesia to the end of the surgery intraoperative
Primary duration of motor block measurement of time required for bromage scale to regress from 3 to 0 1 hour postoperatively
Primary duration of staying in PACU duration of parturient stay in PACU 2 hours postoperatively
Secondary Neonatal Apgar score at 1 minute Neonatal Apgar score will be recorded at 1 minute after delivery. The Apgar score is determined by evaluating the newborn baby on five simple criteria on a scale from zero to two, then summing up the five values thus obtained. The resulting Apgar score ranges from zero to 10. Scores 7 and above are generally normal; 4 to 6, fairly low; and 3 and below are generally regarded as critically low and cause for immediate resuscitative efforts 1 minute post delivery
Secondary Neonatal Apgar score at 5 minutes Neonatal Apgar score will be recorded at 5 minutes after delivery. The Apgar score is determined by evaluating the newborn baby on five simple criteria on a scale from zero to two, then summing up the five values thus obtained. The resulting Apgar score ranges from zero to 10. Scores 7 and above are generally normal; 4 to 6, fairly low; and 3 and below are generally regarded as critically low and cause for immediate resuscitative efforts 1 minute post delivery
Secondary neonatal blood gases fetal cord blood analysis will be performed immediately post-delivery 1 minute post delivery
Secondary incidence of neonatal acidosis incidence of neonatal acidosis (PH<7.2) will be recorded 1 minute post delivery
Secondary incidence of hypotension any occurence of hypotension (systolic blood pressure<80% of baseline) throughout the operation will be recorded intraoperative
Secondary incidence of bradycardia any incidence of maternal bradycardia (heart rate<60/min) will be recorded intraoperative
Secondary need for vasoconstrictor any need for vasoconstrictor during the operation will be recorded intraoperative
Secondary need for atropine any need for atropine during the operation because of bradycardia will be recorded intraoperative
Secondary incidence of nausea/vomiting any occurence of nausea and/or vomiting during the operation will be recorded intraoperative
Secondary incidence of dizziness any occurence of dizziness during the operation will be recorded intraoperative
Secondary incidence of drowsiness any occurence of drowsiness during the operation will be recorded intraoperative
Secondary incidence of discomfort any occurence of discomfort during the operation will be recorded intraoperative
Secondary incidence of shivering any occurence of shivering during the operation will be recorded intraoperative
Secondary need for rescue analgesia in PACU need for rescue analgesia in PACU when VAS scale >4 will be recorded 2 hours postoperatively
Secondary time from spinal anesthesia to rescue analgesia in PACU time from spinal anesthesia to rescue analgesia in PACU will be recorded 2 hours postoperatively
Secondary incidence of neurological symptoms during hospital stay incidence of neurological symptoms during hospitalization will be recorded 5 days postoperatively
Secondary incidence of neurological symptoms 2 months after the operation incidence of neurological symptoms 2 months after discharge from the hospital will be recorded by phone communication 2 months after discharge
Secondary incidence of low back pain incidence of low back pain 2 months after discharge from the hospital will be recorded by phone communication 2 months after discharge
Secondary time from spinal anesthesia to mobilization time from spinal anesthesia to mobilization of parturient will be recorded 2 days postoperatively
Secondary mother's satisfaction from anesthesia mother's satisfaction from anesthesia will be recorded using Likert scale. Likert scale ranges from 1 which is the minimum satisfaction to 4 which is the maximum satisfaction 1 day postoperatively
Secondary gynecologist's satisfaction gynecologist's satisfaction from anesthesia will be recorded using Likert scale. Likert scale ranges from 1 which is the minimum satisfaction to 4 which is the maximum satisfaction 1 hour postoperatively
See also
  Status Clinical Trial Phase
Terminated NCT03772886 - Reducing Cesarean Delivery Rate in Obese Patients Using the Peanut Ball N/A
Completed NCT03631329 - Predictability of Preoperative Carotid Artery Corrected Flow Time for Hypotension After Spinal Anesthesia in Patients Undergoing Cesarean Section
Completed NCT03244540 - Regional Analgesia After Cesarean Section Phase 4
Active, not recruiting NCT03760718 - Chloroprocaine Lavage to Improve Outcomes Related to Operative Cesarean Delivery Early Phase 1
Active, not recruiting NCT04965779 - The Effect of Abdominal Binder Use on Postpartum Pain, Bleeding, and Breastfeeding Success in Cesarean Delivery Women N/A
Terminated NCT01687972 - INSORB Versus Subcuticular Sutures at Cesarean Section Phase 1
Withdrawn NCT01211431 - Post-cesarean Pain Control Via Continuous Infusion of Ropivacain et Diclogenac Into the Wound Versus Intathecal Morphine Phase 4
Completed NCT00987701 - Perineuraxial Anesthesia Fluid Management and Infant Neurobehaviors N/A
Completed NCT00991627 - Different Approaches to Maternal Hypotension During Cesarean Section Phase 4
Completed NCT01049477 - The Effects of Music Therapy on Women's Anxiety Before and During Cesarean Delivery N/A
Terminated NCT00524511 - Comparison Study of Wound Closure at Time of Cesarean Delivery: Dermabond Glue Versus Surgical Staples N/A
Terminated NCT00386477 - Vaginal Cleansing at Cesarean Delivery to Reduce Infection: A Randomized, Controlled Trial N/A
Completed NCT00375986 - A Comparison of Manual vs. Spontaneous Removal of the Placenta at Cesarean Section N/A
Completed NCT00517140 - Vaginal Birth After Caesarean Section - Effect on Maternal Psychosocial Function N/A
Terminated NCT05051150 - Epinephrine Infusion for Prophylaxis Against Maternal Hypotension During Caesarean Section Phase 4
Terminated NCT03695172 - Comparison of TAP, Anterior QL, or ESP Block for Elective Cesarean Section Phase 4
Recruiting NCT06247852 - Persistent Pain After Cesarean Delivery - A Danish Multicenter Cohort Study
Completed NCT06012747 - Pain After Cesarean Section - A Danish Multicenter Cohort Study.
Not yet recruiting NCT05187520 - Naldebain for Control of Post-Cesarean Section Pain Phase 2
Not yet recruiting NCT04999670 - Fascial Closure and Post-caesarean Pain N/A